ZA892023B - Orally administered pharmaceutical agent for iron and magnesium substitutive therapy - Google Patents

Orally administered pharmaceutical agent for iron and magnesium substitutive therapy

Info

Publication number
ZA892023B
ZA892023B ZA892023A ZA892023A ZA892023B ZA 892023 B ZA892023 B ZA 892023B ZA 892023 A ZA892023 A ZA 892023A ZA 892023 A ZA892023 A ZA 892023A ZA 892023 B ZA892023 B ZA 892023B
Authority
ZA
South Africa
Prior art keywords
magnesium
iron
compound
pharmaceutical agent
orally administered
Prior art date
Application number
ZA892023A
Other languages
English (en)
Inventor
Joachim Helbig
Helbig Joachim
Hans Georg Classen
Georg Classen Hans
Original Assignee
Verla Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verla Pharm filed Critical Verla Pharm
Publication of ZA892023B publication Critical patent/ZA892023B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA892023A 1988-03-22 1989-03-16 Orally administered pharmaceutical agent for iron and magnesium substitutive therapy ZA892023B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3809625A DE3809625A1 (de) 1988-03-22 1988-03-22 Oral verabreichbares pharmazeutisches mittel, insbesondere zur eisen- und magnesiumsubstitutionstherapie

Publications (1)

Publication Number Publication Date
ZA892023B true ZA892023B (en) 1989-11-29

Family

ID=6350387

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA892023A ZA892023B (en) 1988-03-22 1989-03-16 Orally administered pharmaceutical agent for iron and magnesium substitutive therapy

Country Status (8)

Country Link
US (1) US5143732A (xx)
EP (1) EP0334177B1 (xx)
AT (1) ATE123416T1 (xx)
DE (2) DE3809625A1 (xx)
DK (1) DK115789A (xx)
ES (1) ES2072270T3 (xx)
PT (1) PT90096B (xx)
ZA (1) ZA892023B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4201504C2 (de) * 1992-01-21 1997-04-30 Protina Chemische Ges Mbh Magnesiumpräparat
DE19504936C1 (de) * 1995-02-15 1996-05-15 Woerwag Pharma Gmbh Arzneimittel auf der Grundlage von Magnesiumchlorid
WO2000033818A1 (en) 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
US6579905B1 (en) * 2001-11-19 2003-06-17 Mcmains Michael B. Method for the prevention or treatment of hypomagnesemia in pediatric patients and in patients with G-tubes or NG-tubes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH294891A (de) * 1949-06-30 1953-11-30 Hilppa Pirhonen Verfahren zur Herstellung von Nährsalzpräparaten.
JPS57156419A (en) * 1981-03-24 1982-09-27 Kyowa Chem Ind Co Ltd Remedy for sideropenia
DE3238118A1 (de) * 1982-10-14 1984-04-19 Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing Verfahren zur herstellung von komplexverbindungen aus aminodicarbonsaeuren, zweiwertigen metallionen und halogenidionen
JPS606619A (ja) * 1983-06-27 1985-01-14 Kyowa Chem Ind Co Ltd 鉄分欠乏症処置剤及びその製法
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals

Also Published As

Publication number Publication date
DK115789A (da) 1989-09-23
EP0334177B1 (de) 1995-06-07
EP0334177A3 (en) 1990-05-30
US5143732A (en) 1992-09-01
ATE123416T1 (de) 1995-06-15
PT90096A (pt) 1989-11-10
EP0334177A2 (de) 1989-09-27
DE3809625A1 (de) 1989-10-05
DK115789D0 (da) 1989-03-09
DE58909272D1 (de) 1995-07-13
ES2072270T3 (es) 1995-07-16
DE3809625C2 (xx) 1990-03-22
PT90096B (pt) 1994-10-31

Similar Documents

Publication Publication Date Title
AU2584192A (en) Bone-growth-stimulating composition
CA2039197A1 (en) Pharmaceutic Formulation for the Treatment of Alcoholism
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
KR930007441A (ko) 의약품
CA2004239A1 (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma, and pharmaceutical compositions useful in such treatment
CA2125662A1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
ZA898667B (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract and pharmaceutical compositions useful in such treatment
SE9002500L (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
CA2135614A1 (en) Use of urodilatin in pulmonary and bronchial diseases
RO117760B1 (ro) Metodă pentru tratamentul unei afecţiuni de neurotransmisie serotoninergică defectivă
ZA892023B (en) Orally administered pharmaceutical agent for iron and magnesium substitutive therapy
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
EP0484112A3 (en) Use of lithium in the treatment or prophylaxis of molluscum contagiosum
HUT63058A (en) Process for producing pharmaceutical compositions for treating osteoporosis, comprising pharmaceutically applicable alkalinizing potassium salt
AU6724581A (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
ZA885590B (en) Pharmaceutical composition intended for the prevention and treatment of bacterial or viral diseases
HRP970171A2 (en) Use of bradykinin antagonists for the preparation of medicaments to treat chronic fibrogenetic liver disease and acute liver disease
KR880009652A (ko) 3-5-디클로로메토트랙세이트를 사용하는 류마티스성 관절염 치료법 및 그에 유용한 조성물
IT1267664B1 (it) Composizione a base di fosfocreatina e suo uso farmaceutico
DE3786168D1 (de) Verwendung von para-aminobenzoesaeure zur herstellung eines arzneimittels zur bekaempfung von photoallergien.
Ciugudeanu et al. Evaluation of chronic toxicity of morpholine.).
RU95115404A (ru) Применение рилузола в качестве средства для лечения болезни паркинсона и синдромов паркинсона, способ получения лекарственного средства
RU93011592A (ru) Способ лечения эндогенных психозов